Medications for Primary Insomnia

6 results

  • ambien

    (zolpidem tartrate)
    sanofi-aventis U.S. LLC
    AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep initiation. It effectively reduces sleep latency for up to 35 days, as demonstrated in controlled clinical studies lasting 4–5 weeks.

  • ambien

    (zolpidem tartrate)
    sanofi-aventis U.S. LLC
    AMBIEN CR (zolpidem tartrate extended-release tablets) is indicated for the short-term treatment of insomnia, particularly for difficulties with sleep onset and/or maintenance, as measured by wake time after sleep onset. Clinical trials supporting its efficacy lasted up to 24 weeks.

  • belsomra

    (suvorexant)
    Merck Sharp & Dohme LLC
    BELSOMRA® (suvorexant) is indicated for treating insomnia, specifically for individuals who have trouble with sleep onset and/or sleep maintenance.

  • dayvigo

    (lemborexant)
    Eisai Inc.
    DAYVIGO is indicated for the treatment of adult patients with insomnia, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance.

  • quviviq

    (Daridorexant)
    Idorsia Pharmaceuticals Ltd
    QUVIVIQ is indicated for the treatment of insomnia in adult patients, specifically addressing issues with sleep onset and/or sleep maintenance.

  • silenor

    (doxepin hydrochloride)
    Currax Pharmaceuticals LLC
    SILENOR is indicated for the treatment of insomnia characterized by difficulty maintaining sleep, with clinical trials supporting its efficacy for up to 3 months.